Navigation Links
Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50
Date:5/21/2008

Analysis of Cardiac Adverse Events in TORCH Showed Frequency Highest in

Placebo Group

TORONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRNewswire-FirstCall/ -- The use of Advair Diskus(R) 500/50 (fluticasone propionate and salmeterol inhalation powder) was associated with the lowest number of cardiovascular adverse events compared to other treatment arms in a post-hoc analysis of data from the TOwards a Revolution in COPD Health (TORCH) study presented at the International Conference of the American Thoracic Society meeting in Toronto today.

The TORCH study followed more than 6,000 patients with chronic obstructive pulmonary disease (COPD) over a 3-year period. Because cardiovascular mortality is a common cause of death in patients with COPD, investigators assessed how Advair or its component medications affected the rate of cardiac adverse events compared to the individual components and placebo in this analysis.

The results found that 17 percent of patients treated with Advair reported a cardiac adverse event, compared with 21 percent of those in the placebo group, 19 percent of those in the salmeterol group and 20 percent of those in the fluticasone propionate group. The rate of cardiac death was also lower in the Advair arm as compared with the placebo arm (4% vs. 5%).

"Because the TORCH study followed over 6,000 patients for 3 years, it gives us the unique opportunity to look for cardiovascular trends in patients with COPD. After looking closely at all of the data, we certainly do not see any increase in cardiovascular risks associated with Advair or salmeterol," said Gary Ferguson, MD, Pulmonary Research Institute of Southeast Michigan and member of the TORCH steering committee. "In fact, Advair had the lowest number of cardiovascular adverse effects and we see this as an important finding."

Advair contains two medications, an inhaled corticosteroid and a long-acting beta-agonist, that w
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
2. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
3. LOreal USA Announces Three-Year Support of Womens Dermatologic Society Foundation Community Outreach
4. Alsius Corporation Awarded Three-Year Agreement With MedAssets Supply Chain Systems
5. Independence Blue Cross, Jefferson Health System Reach Agreement on New Three-Year Contracts
6. ABMS Assembly Votes in Favor of Three-Year Initiative to Enhance Public Trust in the Board Certification Process
7. Penn study finds pro-death proteins required to regulate healthy immune function
8. New study shows promise in reducing surgical risks associated with surgical bleeding
9. Study, meta-analysis examine factors associated with death from heatstroke
10. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
11. Study says COPD testing is not measuring up
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... (HealthDay News) -- Just a few extra cups of ... an autoimmune liver disease known as primary sclerosing cholangitis ... Mayo Clinic in Rochester, Minn., found that drinking coffee ... disease, which can lead to cirrhosis of the liver, ... not prove a cause-and-effect relationship. "While rare, ...
(Date:5/18/2013)... 18, 2013) There are significant cost and ... to diagnose or treat gastrointestinal problems, according to ... , A study by New York Presbyterian Hospital ... testing may substantially reduce the cost and risk ... is believed to affect nearly 25 percent of ...
(Date:5/18/2013)... ID (PRWEB) May 18, 2013 ... when it comes to safety and comfort of ... requirements and provides clients with an effective and ... This is an integrated, turnkey communications solution ... care, while allowing residents independence and privacy. ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Transvaginal ... products continue to move forward in a consolidated litigation ... Liebhard LLP reports. According to a notice on the ... Ethicon pelvic mesh litigation will be held on Wednesday, ... have been filed in the proceeding on behalf of ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & Forecast (2010 ... restraints, and opportunities in North America, Europe, Asia, & ... 89 market data tables , ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers ... healthcare IT market is expected to grow from $99.6 ...
Breaking Medicine News(10 mins):Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3
... Inc., a global provider of image management services ... announced that it has made a contribution to ... Vascular Association (AVA). Open the Pathway is an ... M2S has a long-term commitment to vascular treatment ...
... legislators announced a budget deal that includes temporary revenues in ... them permanent, SEIU members and community allies from around the ... in Sacramento and the Governor,s offices in Los Angeles, Riverside, ... week.The rallies are an effort to stop the bad budget ...
... incentivesPORTLAND, Ore., Feb. 11 Regence BlueCross BlueShield of ... the Boys and Girls Clubs of Central Oregon. The ... develop healthy habits and decision making skills, and improve ... impact that our choices have on health, and we,re ...
... better diagnosis, treatment for heart patients , , WEDNESDAY, Feb. ... contrast echocardiography had a significant impact on the diagnosis ... new study found. , Echocardiography bounces sound waves into ... moving heart. If that image isn,t clear enough, it ...
... Program Teaches Earth-Friendly Health ChoicesMIDLAND, Mich., Feb. 11 ... looking for ways to go green. By implementing ... program ( www.HealthEnhancementSystems.com ), Green ... www.greenplanetwellness.com/?from=nw_021109 ), participants learn small steps ...
... Calif., Feb. 11 Valeant Pharmaceuticals International (NYSE: ... a conference call on Tuesday, February 24, 2009 at ... for the 2008 fourth quarter and year.The dial-in number ... code 83660030. International callers should dial ...
Cached Medicine News:Health News:M2S, Inc. Makes Contribution to American Vascular Association 2Health News:M2S, Inc. Makes Contribution to American Vascular Association 3Health News:Boys and Girls Clubs of Central Oregon Get $10K Regence Grant 2Health News:Study Brings Value of Echocardiography Into Focus 2Health News:Green Planet Wellness Helps Employers Have Big Environmental Impact 2Health News:Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009 2
(Date:5/17/2013)... , May 17, 2013  Orexigen® Therapeutics, Inc. (Nasdaq: ... a company overview at the UBS Global Healthcare Conference in ... for Wednesday, May 22 nd at 11 a.m. Eastern ... of the presentation, please visit the Investor Relations section of ... will be available for 14 days after the event. ...
(Date:5/17/2013)... /PRNewswire-iReach/ -- United Medical Education, a company that provides ... Advanced Life Support (PALS) and Basic Life Support (BLS), ... online course manuals. In order to gain access ... an account with the company. By offering the free ... Education is setting a precedent among similar companies. ...
(Date:5/17/2013)... , May 17, 2013  Serving a region of ... Rico , Caribbean Imaging and Radiation Therapy (CIRT, ... therapy capabilities with the acquisition of an Elekta Versa HD™ ... Versa HD offers clinicians the versatility to deliver conventional therapies ... while also enabling treatment of highly complex cancers that require ...
Breaking Medicine Technology:ACLS Online Course Manuals are Now Available at No Cost through United Medical Education 2Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2
... a First, Immunotherapy Works Against Neuroblastoma-- PHILADELPHIA, May 28 ... for an experimental therapy using elements of the body,s ... neuroblastoma, a challenging cancer of the nervous system.John M. ... of Philadelphia, co-authored the phase 3 clinical trial, which ...
... Survival, Disease Control and Neurotoxicity Data To Be ... Support Picoplatin as a Neuropathy-Sparing Alternative to Oxaliplatin ... Management Team to Host Analyst and Investor Briefing ... SOUTH SAN FRANCISCO, Calif., May 28 Poniard ...
Cached Medicine Technology:New Therapy Enlists Immune System to Boost Cure Rate in a Childhood Cancer 2New Therapy Enlists Immune System to Boost Cure Rate in a Childhood Cancer 3Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 5Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 6
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: